Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOX66 and EBRT in mCRPC and Solid Tumors
NCT04957290Phase 2Terminated
- Sponsor
- Noxopharm Limited
- Start
- Oct 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of idronoxil in metastatic castration-resistant prostate cancer (mCRPC), breast cancer, non-small cell lung cancer (NSCLC), solid tumor, sponsored by Noxopharm Limited. Started Oct 2021; status: terminated.
02
Drugs
idronoxil
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)breast cancernon-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT04957290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04957290.